Biology subjects

Kliewer, A.

Publications and source records attributed to Kliewer, A..

6 recordsLinked to original sources

bioRxiv2025

Robust functional ultrasound imaging in the awake and behaving brain: a systematic framework for motion artifact removal

Functional ultrasound imaging (fUSI) is a promising tool for studying brain activity in awake and behaving animals, offering insights into neural dynamics that are more naturalistic than those obtained under anesthesia. However, motion artifacts pose a significant challenge, introducing biases that can compromise the integrity of the data. This study provides a comprehensive evaluation and benchmarking of strategies for detecting and removing motion artifacts in transcranial fUSI acquisitions of awake mice. We evaluated 792 denoising strategies across four datasets, focusing on clutter filtering, scrubbing, frequency filtering, and confound regression methods. Our findings highlight the superior performance of adaptive clutter filtering and aCompCor confound regression in mitigating motion artifacts while preserving functional connectivity patterns. We also demonstrate that high-pass filtering is generally more effective than band-pass filtering in the presence of motion artifacts. Additionally, we show that with effective clutter filtering, scrubbing may become optional, which is particularly beneficial for experimental designs where motion correlates with conditions of interest. Based on these insights, we propose four optimized denoising paradigms tailored to different experimental constraints, providing practical recommendations for enhancing the reliability and reproducibility of fUSI data. Our findings challenge current practices in the field and have immediate practical implications for existing fUSI analysis workflows, paving the way for more sophisticated applications of fUSI in studying complex brain functions and dysfunctions in awake experimental paradigms.

neuroscience↗

bioRxiv2024

Opioid-Induced Inter-regional Dysconnectivity Correlates with Analgesia in Awake Mouse Brains

The {micro}-opioid receptor (MOP) is crucial for both the therapeutic and addictive effects of opioids. Using a multimodal experimental approach, here we combined awake functional ultrasound (fUS) imaging with behavioral and molecular assessments, to examine opioid-induced changes in brain activation and functional connectivity (FC). Morphine, fentanyl, and methadone induce significant dose- and time-dependent reorganization of brain perfusion, oscillations and FC in awake mice. Notably, opioids induce a transient, region-specific hyperperfusion, followed by a consistent MOP-specific dysconnectivity marked by decreased FC of the somatosensory cortex to hippocampal and thalamic regions, alongside increased subcortical and intra-cortical FC. These FC changes temporally correlate with generalized brain MOP activation and analgesia, but not with hypermobility and respiratory depression, suggesting a reorganization of inter-regional FC as a key opioid effect.

neuroscience↗

bioRxiv2022

A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening

Analysis of agonist-driven phosphorylation of G protein-coupled receptors (GPCRs) can provide valuable insights into the receptor activation state and ligand pharmacology. However, to date, assessment of GPCR phosphorylation using high-throughput applications has been challenging. We have developed and validated a bead-based immunoassay for the quantitative assessment of agonist-induced GPCR phosphorylation that can be performed entirely in multiwell cell culture plates. The assay involves immunoprecipitation of affinity-tagged receptors using magnetic beads followed by protein detection using phosphorylation-state-specific and phosphorylation state-independent anti-GPCR antibodies. As proof of concept, five prototypical GPCRs (MOP, C5a1, D1, SST2, CB2) were treated with different agonists and antagonists, and concentration-response curves were generated. We then extended our approach to establish selective cellular GPCR kinase (GRK) inhibitor assays, which led to the rapid identification of a selective GRK5/6 inhibitor (LDC8988) and a highly potent pan-GRK inhibitor (LDC9728). In conclusion, this versatile GPCR phosphorylation assay can be used extensively for ligand profiling and inhibitor screening.

pharmacology and toxicology↗

bioRxiv2022

In situ Visualization of therapeutic drug effects using phosphosite-specific GPCR antibodies

G protein-coupled receptors (GPCRs) are important signal transducers that are phosphorylated upon activation at intracellular serine and threonine residues. Although antibodies that specifically recognize the phosphorylation state of GPCRs have been available for many years, efficient immunolocalization of phosphorylated receptors in their tissues of origin has not been possible. Here, we show that phosphorylation of receptors is highly unstable during routine immunohistochemical procedures, requiring the use of appropriate phosphatase inhibitors particular during tissue perfusion, post-fixation, and cryoprotection but not during immunostaining of tissue sections. We provide proof of concept using -opioid receptor (MOP) and cannabinoid receptor 1 (CB1) antibodies. Indeed, three of four well-characterized phosphosite-specific MOP antibodies, including pS375-MOP, pT376-MOP, and pT379-MOP, showed robust neuronal immunostaining in brain and spinal cord sections of opioid-treated mice only after inclusion of phosphatase inhibitors. We then extended this approach to the CB1 receptor and demonstrated that one of three newly-generated phosphosite-specific CB1 antibodies, namely pS425-CB1, showed striking staining of fibers and varicosities in brain slices from cannabinoid-treated mice. Although subsequent experiments showed that phospho-CB1 immunostaining was less sensitive to phosphatases, we conclude that the use of phosphatase inhibitors should always be considered in the development of immunohistochemical procedures for new phosphosite-specific GPCR antibodies. In summary, we anticipate that this improved protocol will facilitate the widespread use of phosphorylation state-specific antibodies to monitor the activation of endogenous GPCRs under physiological and pharmacological conditions. Our approach may also prove useful to confirm target engagement of GPCR drug candidates in native tissues.

pharmacology and toxicology↗

bioRxiv2021

GRK2/3/5/6 knockout: The impact of individual GRKs on arrestin-binding and GPCR regulation

G protein-coupled receptors (GPCRs) comprise the largest family of transmembrane receptors and represent major drug targets. Upon ligand stimulation, GPCRs activate G proteins and undergo a complex regulation by interaction with GPCR kinases (GRKs) and formation of receptor-arrestin complexes. For many GPCRs, this mechanism triggers receptor desensitisation, internalisation, and possibly a second intracellular signalling wave. Here we created eleven different HEK293 knockout cell clones for GRK2, 3, 5, and 6 individually and in combination. These include four single, two double, four triple, and the quadruple GRK knockout. The statistical evaluation of {beta}-arrestin1/2 interactions for twelve different receptors grouped the tested GPCRs into two main subsets: those for which {beta}-arrestin interaction was mediated by either GRK2, 3, 5, or 6 and those that are mediated by GRK2 or 3 only. Interestingly, the overexpression of specific GRKs was found to induce a robust, ligand-independent {beta}-arrestin interaction with the V2R and AT1R. Finally, using GRK knockout cells, PKC inhibitors, and {beta}-arrestin mutants, we present evidence for differential AT1R-{beta}-arrestin2 complex configurations mediated by selective engagement of PKC, GRK2, or GRK6. We anticipate our novel GRK-knockout platform to facilitate the elucidation of previously unappreciated details of GRK-specific GPCR regulation and {beta}-arrestin complex formation.

cell biology↗

bioRxiv2021

Microglia control cerebral blood flow and neurovascular coupling via P2Y12R-mediated actions

Microglia, the main immunocompetent cells of the brain regulate neuronal function in health and disease, but their contribution to cerebral blood flow (CBF) remained elusive. Here we identify microglia as important modulators of CBF both under physiological conditions and during hypoperfusion. We show that microglia establish direct purinergic contacts with cells in the neurovascular unit that shape cerebral perfusion in both mice and humans. Surprisingly, the absence of microglia or blockade of microglial P2Y12 receptor (P2Y12R) substantially impairs neurovascular coupling in the barrel cortex after whisker stimulation. We also reveal that hypercapnia, which is associated with acidification, induces microglial adenosine production, while depletion of microglia reduces brain pH and impairs hypercapnia-induced vasodilation. Furthermore, the absence or dysfunction of microglia markedly impairs adaptation to hypoperfusion via P2Y12R after transient unilateral common carotid artery occlusion, which is also influenced by CX3CR1-mediated actions. Thus, our data reveal a previously unrecognized role for microglia in CBF regulation with broad implications for common neurological diseases.

neuroscience↗